Showing results (21-30 of 70) with videos related to
Sort By:
Pageof 7
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2014
Modelling the natural history of primary progressive multiple sclerosisKatharine E Harding, Mark Wardle, Perry Moore, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2009
Very long chain fatty acid levels in patients diagnosed with multiple sclerosisAlastair Wilkins, Gillian Ingram, Anny Brown, et al.Brain Communications|May 7, 2021
Tract-specific MRI measures explain learning and recall differences in multiple sclerosisMia Winter, Emma C Tallantyre, Thomas A W Brice, et al.International Journal of MS Care|November 3, 2016
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' ExperiencesFreya Davies, Fiona Wood, Katherine E Brain, et al.International Ophthalmology|October 13, 2016
Alemtuzumab-induced remission of multiple sclerosis-associated uveitisMark D Willis, Trevor P Pickersgill, Neil P Robertson, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2014
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UKLiene Elsone, Joanna Kitley, Sebastian Luppe, et al.Multiple Sclerosis and Related Disorders|May 1, 2020
Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohortEmma C Tallantyre, Daniel Castle, Paul Karamura, et al.Journal of the Neurological Sciences|May 20, 2020
Seasonal distribution of attacks in aquaporin-4 antibody disease and myelin-oligodendrocyte antibody diseaseGiordani Rodrigues Dos Passos, Liene Elsone, Sebastian Luppe, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 9, 2019
Cerebrospinal fluid complement system biomarkers in demyelinating diseaseWioleta Milena Zelek, Dina Fathalla, Angharad Morgan, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2018
Sarcoidosis following alemtuzumab treatment for multiple sclerosisMark D Willis, Ben Hope-Gill, Patrick Flood-Page, et al.Pageof 7